ArticleHealth economics review2025
The cost of being gluten-free: a hedonic pricing analysis of food products for celiac patients.
Article in Health economics review, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe gluten-free diet (GFD) has gained interest in recent years. While evidence showing that the GFD has a positive impact on everybody's health is weak, people with specific gluten-related disorders may benefit from it. As the only available treatment for celiac disease, the GDF can however not be followed without any additional cost.
methodTo measure it, we collected a rich database of gluten-free and gluten-containing products on the Swiss retail market. Using a hedonic pricing method, we disentangled the price of these products and estimated the gluten-free premium.
resultsWe show that gluten-free products are on average 79% more expensive than regular products, which leads to an annual food-budget increase of CHF 421 (approx. the same in USD) (+ 77%) per patient.
conclusionThese results highlight the need to reflect on the social policies accompanying celiac disease in Switzerland, as there is currently no support from the disability or health insurance for these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.